Sorafenib as adjuvant therapy following radiofrequency ablation for recurrent hepatocellular carcinoma within Milan criteria: a multicenter analysis.

Qunfang ZhouXiaohui WangRuixia LiChenmeng WangJuncheng WangXiaoyan XieYali LiShaoqiang LiXianhai MaoPing Liang

Published in: Journal of gastroenterology (2022)

Adjuvant sorafenib after RFA was superior to RFA alone in improving survival outcomes in patients with recurrent HCC within Milan criteria after initial hepatectomy. Subgroup analyses concluded that patients with high risk score had significantly longer survival from sorafenib administration.

Keyphrases

radiofrequency ablation
early stage
clinical trial
randomized controlled trial
free survival
double blind
study protocol